• EverGen Infrastructure have expanded its operations to encompass organic waste processing, through its Sea to Sky Soils facility
• Sea to Sky Soils, which is operated in partnership with the Lil’wat First Nation, processes organic material into a wide variety of quality soils, compost and landscape material
• The waste processor recently signed an agreement with a BC district ensuring the supply of over 10,000 tonnes of organic waste feedstock per annum over the next 3 years
• With EverGen playing an increasingly crucial role in furthering Canada’s net zero ambitions, the company’s CEO Chase Edgelow was recently recognized in The Global and Mail’s annual list of 50 Changemakers

EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), has long operated at the forefront of Canada’s renewable natural gas (“RNG”) industry. Whilst relatively nascent in nature, the renewable natural gas sector – comprising of processed biogas sourced from landfills, dairy farms and organic waste, has experienced tremendous growth in recent years with production facilities increasingly being rolled out across the U.S. and Canada. In 2021 alone, RNG production capacity in the United States swelled to approximately 660 million gallons gasoline equivalents (“GGE”), a 20 percent increase relative to the prior year. Since commencing operations 12 years ago, EverGen has been an active participant in the sector’s exponential growth trajectory. Boasting 4 revenue generating assets already in operation, the company has recently announced plans to grow its cumulative gross RNG generating capacity to 480,000 gigajoules of energy per annum in the near future, a process which could grow the company’s EBITDA by upwards of 300 percent (https://ibn.fm/p5DyG).

Whilst it has established itself as a mainstay within the RNG field, EverGen Infrastructure have sought to adopt an increasingly holistic view surrounding the renewable energy and waste processing industry. In early 2022, Canada announced its goal to decrease the quantity of waste deposited in its landfills by 30 percent as of 2030 and 50 percent by 2040 (https://ibn.fm/6Dqwr). As part of that overarching ambition, EverGen have founded Sea to Sky Soils, an organic waste processing site operated in partnership with Lil’wat First Nation, seeking to transform and process organic material into high quality soils, compost and landscape materials destined for use by farmers, home gardeners, landscapers and developers.

The business has quickly become one of the largest regional processors of organics within Canada’s British Columbia region, recently announcing that it has signed multiple contracts with a BC regional district for the processing of organic waste at the facility, which provides over 10,000 tonnes per annum (https://ibn.fm/ifTVW). The contract will provide Sea to Sky Soils with increased certainty on the supply of organic feedstock through 2025 with a preferred partner.

“Contracts such as this de-risk our core business and represent another step towards our goal of providing solutions for over 300,000 tonnes of organic waste per annum in the region,” Stated Edgelow.

Through projects such as its Fraser Valley biogas facility, which converts the methane produced by food scraps and manure into RNG and now, its Sea to Sky Soils facility, EverGen Infrastructure has become an integral part of the mission towards achieving Canada’s Net Zero ambitions in the near future. As such, it comes as little surprise that EverGen Infrastructure Co-founder Chase Edgelow was recently recognized as one of 50 Changemakers in The Global and Mail’s annual list. The ambition of the list has been to recognize the activists, executives, entrepreneurs, and academics who have single-mindedly devoted themselves towards making the world a better place. Through its ambition towards transforming the world’s energy consumption and making the earth a cleaner home for all, EverGen Infrastructure certainly made the cut (https://ibn.fm/EPSMh).

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Eloro Resources saw its corporate listing upgraded to trade on the TSX exchange as of March 6, 2023
• The uplisting to the TSX main board provides the company with access to greater stock liquidity and increases its visibility amongst larger institutional investors
• The upgrade marks the latest feat for Eloro Resources, with the company having successfully completed a C$10.9mn capital raising in January
• Eloro Resources are aiming to publish their initial resource estimates for their Iska Iska project by the end of 1Q 2023

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, recently revealed that the company had seen its corporate listing upgraded to trade on the TSX exchange from the TSX-V market as of Monday, March 6th, 2023. The upgrade to the TSX or Toronto Stock Exchange marks a significant milestone for Eloro Resources, enabling the company to access a broad array of new domestic and global investors which may have not previously been able to invest in the stock whilst simultaneously, opening up a new financing avenue for the firm.

The Toronto Stock Exchange (“TSX”) has long distinguished itself as the flagship Canadian stock market; however and typically, access to the market has been limited to well-established corporates boasting a market capitalization of over $50 million. On the other hand, the TSX Venture Exchange (“TSXV”), formerly known as the Canadian Venture Exchange, has dedicated itself towards providing earlier-stage companies with access to public venture capital in an effort to help spur growth and establish a footprint within the Canadian capital market space. Notably, the majority of TSXV companies are valued at between $500,000 and $20 million, whilst enjoying a corporate disclosure burden which is far less stringent than those to which TSX-listed companies are subject to.

Ove the years, the TSX has welcomed over 650 TSX-V listed companies; today, approximately 20% of all companies included within the TSX composite index trace their roots to the TSX-V. To graduate to the primary exchange, TSX-V listed companies must first meet the specific TSX listing requirements related to their particular industry, following which they must submit an application, audited financial statements and recent quarterly statements to be reviewed by the TSX’s board – a lengthy yet rewarding process which Eloro Resources have successfully navigated in recent months.

The upgrade in its stock listing marks the latest feat for Eloro Resources, with the company having announced earlier in January that it had concluded its fully-underwritten primary share placement, raising total gross proceeds of C$10,919,570. At the time the company revealed that the net proceeds derived from the offering would be destined towards exploration and development purposes at the company’s ongoing mining projects in Bolivia as well as for general working capital purposes.

Since commencing its inaugural drill program at the Iska Iska site in September 2020, Eloro Resources have completed a cumulative 84,495 meters of drilling across 122 holes at Iska Iska (https://ibn.fm/hu4O3), with the company anticipating the publication of the initial resource estimates by the end of March 2023. The company have now sought to shift shift their focus towards exploring the feasibility of identifying a second potential world-class tin deposit at Iska Iska, in addition to the already identified, silver-tin polymetallic deposit in Santa Barbara (n.b. a location within the project site).

Following the company’s recent uplisting to the Toronto Stock Exchange main board, successful capital raising exercise and benefitting from exponential demand growth for both, silver and tin as a result of the ongoing global transition towards renewable energy sources, Eloro Resources look well placed to capitalize on any forthcoming resources discoveries in the coming months.

For more information, visit the company’s website at www.EloroResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

• Battery Mineral Resources is focused on the discovery, acquisition and development of battery metal projects in North America, South America and South Korea
• The company’s flagship Punitaqui mine has the potential to generate an annual EBITDA of up to $50 million at or above a copper price of $4.25/lb. with production targeted for H2 of this year
• BMR is working to secure final funding for the restart of mining and resumption of copper concentrate production from its Punitaqui complex; it in advanced discussions with several parties and has the goal of closing a funding agreement in the coming months
• In the second half of 2022, BMI made significant progress toward increasing and improving its human and financial resources, as well as permitting, metallurgy and ESG initiatives
• The company is strategically positioning itself to take advantage of renewed positive market sentiment for near term copper pricing

Battery Mineral Resources (TSX.V: BMR) (OTCQB: BTRMF) is a battery minerals company providing shareholders exposure to the global mega-trend of electrification while being focused on growth through cash-flow, exploration and acquisitions in favorable mining jurisdictions.

The company’s mission is the discovery, acquisition and development of battery metals (namely copper, cobalt, lithium, and graphite) in North America, South America and South Korea. It aims to become a leading low-cost producer of high quality, ethically sourced battery metals from high-grade, low impact mines in stable jurisdictions that are close to major consumer industries.

BMR is headquartered in Vancouver, British Colombia, with a portfolio of projects spanning Canada, the U.S., Chile and South Korea.

Project Portfolio

BMR’s current focus is the restart of its Punitaqui copper mine in Chile, as well as the exploration and development of its cobalt, lithium and graphite assets in North America and South Korea. The company also continues to identify and evaluate new project opportunities in its operating jurisdictions.

Its current portfolio includes:

Chile – Copper

BMR’s 100%-owned Punitaqui copper mine, acquired in March 2021, has the potential to generate an annual EBITDA of up to $50 million at or above a copper price of $4.25/lb. The company’s flagship project, the Punitaqui mine has been the subject of numerous milestones in recent months, including:

• BMR funded and completed a successful 32,526m resource drill program in 2022. Metallurgical testwork has confirmed the ability to produce excellent copper concentrates from each of the five zones tested, including recoveries ranging from 81% on the low end at Cinabrio Norte up to 96.5% at the Dalmacia deposit.
• The company in August 2022 reported the results of its first ever NI 43-101-compliant resource estimate for the underground deposits at its Punitaqui copper mining complex of 6.2 million tonnes grading 1.14% Cu in indicated category, along with 3.1 million tonnes grading 0.93% Cu in the inferred category. This resource estimate greatly exceeded management goals.
• In September 2022, BMR announced the approval by the Chilean Environment Assessment Service for the Environmental Impact Declaration (“DIA”) pertaining to mining at the company’s Cinabrio mine and San Andres deposit. The approval of the DIA allows BMR to move forward with starting mining operations in 2023 and restarting the mill at its Punitaqui copper mining complex soon after.
• BMR is focused on securing the final funding for the restart of mining and resumption of copper concentrate production at Punitaqui. Once this funding is received, BMR aims to complete mine rehabilitation and development in four to six months, with the ramp up from first production to the full production rate of 20-25 million pounds of copper in concentrate per annum to require a further four to six months.

“From exploration, engineering, community and permitting successes to realizing several non-dilutive means of funding to allow BMR to advance the project, our team looks forward to taking advantage of the renewed positive market sentiment for near term copper pricing and placing ourselves in a strong position to participate in a robust copper sector in 2023,” CEO Martin Kostuik stated in a news release.

Canada – Cobalt/Silver

Between 2016 and April 2018, BMR acquired through claim staking, option, joint venture and direct purchase the largest regional land holding in the historic home of high-grade cobalt-silver veins in Canada known locally as the Cobalt Embayment.

As of February 2023, BMR controlled a land package totaling 9 properties with 4,086 tenements that encompass an area of 84,003.39Ha. The key projects within the land package include McAra, Gowganda, Elk Lake, Fabre and Wilder. From 2017-2022, a total of 412 holes/51,452.34m were drilled on eight projects/20 targets. In addition, a total of 26,709 Line-Km of airborne geophysical surveys & 1,324.84sqkm of LiDAR topography was flown. Follow-up ground geophysical surveys resulted in a total of 37 surveys (514.64 Line-Km) being completed.

Initial NI 43-101 compliant resource defined at McAra (M&I Resource of 1,124,000lbs Co) was detailed in a Technical Report on Cobalt Exploration Assets in Canada dated as of February 5, 2021, with an effective date of October 31, 2020, prepared by SRK Consulting – G Cole PGeo (APGO#1416).

Idaho – Cobalt

BMR holds the Bonanza and East Fork properties located in the historic cobalt-copper-gold Blackbird mining district (Blackbird Mine from 1902-1963 produced 17Mt grading 0.7% Co, 1.4% Cu, and 1 g/t Au) located about 30 kilometers west of Salmon, Idaho. The Bonanza project is immediately adjacent to Jervois Global’s Idaho Cobalt Operations, the United States’ only operating primary cobalt mine. At Bonanza, there are seven mineralized sites within an area over three kilometers wide that extends along a gabbro dyke striking continuously for over six kilometers northward from Noranda’s historic Blackbird Cobalt/Copper mine. The showings on the project are Bonanza Copper Tunnels, Tinker’s Pride, Bonanza Copper #25, Indian Creek, Gray Copper, Blackrock #4 and Papoose #’s 1-4.

From 2018-2021, BMR’s Bonanza Exploration included 550 line-km of airborne magnetics and radiometrics followed up by surface exploration that included rock sampling, soil sampling, channel sampling of historic workings and 3.6km of time domain induced polarization geophysics.

The two properties cover 12 significant cobalt-copper prospects within the known mineralized zone. Both of the BMR Idaho cobalt belt properties host excellent high-grade discovery potential.

South Korea – Graphite

BMR has 100% ownership of the Guemam and Taehwa graphite exploration projects containing high-purity flake graphite deposits. Both assets are past-producing mines with existing local infrastructure and near-term production potential.

Nevada – Lithium

The company’s Amargosa lithium project is in the southern Basin & Range province and central Mojave Desert of Nevada. It is an early-stage exploration opportunity in a favorable region that hosts numerous lithium occurrences, including the Clayton Valley lithium deposit owned by Cypress Development Corp., as well as a major nearby lithium brine mine currently in production called the Silver Peak mine held by Albermarle Corp., one of the world’s largest lithium producers.

Market Opportunity

Near-term forecasts for the copper sector are extremely bullish, with stalwart Wall Street firms such as Goldman Sachs and Bank of America projecting record highs in the coming months. A combination of short-term supply deficits and long-term energy transition demand are expected to buck the downward pressures that have impacted copper prices in recent years.

Goldman in December 2022 forecast a 178K metric ton deficit in the copper market in 2023, causing the firm to raise its 12-month target to $11K/ton and its average price for calendar 2023 to $9,750/ton.

With China likely to continue accelerating efforts to restock depleted inventories in the wake of its COVID-19 reopening and a sustained push toward electrification around the globe placing a strain on supply, BMR is uniquely positioned to capitalize through the anticipated restart of operations at its Punitaqui copper mine.

Management Team

JMartin Kostuik is CEO and a Director of BMR. He brings to the company nearly three decades of diversified experience in the mining industry as a mining engineer and senior executive. Prior to joining BMR, Mr. Kostuik served as president and director of Arizona Gold Corporation and as CEO and director of Rupert Resources Limited. He built a broad base of experience in operations, engineering, exploration and capital projects with various companies including Luna Gold (Equinox), Barrick Gold Corporation, Taseko Mines Limited and DMC Mining Services. Mr. Kostuik earned his B.S. in Mining Engineering from Queen’s University and his M.B.A. from the University of Tennessee.

JMax Satel is the company’s CFO. He has over 18 years of experience as a successful natural resources-focused executive, most recently serving as EVP Corporate Development & Investor Relations for Arrow Exploration Corp., a TSX Venture- and AIM-listed oil & gas company with operations in Colombia and Canada. Prior to joining Arrow, Mr. Satel was principal and co-founder of Bordeaux Capital Inc., a Toronto-based advisory firm focused on the capital needs of companies across the natural resources sector, where he led and executed project financing advisory mandates involving global financial institutions and private equity funds. He earned a Bachelor of Commerce in Finance and Economics from the University of Toronto.

Jacob Willoughby is VP Corporate Development & Strategy for BMR. He brings to the company nearly 17 years of diversified experience in mining capital markets, including over eight years as a mining analyst covering exploration and development companies globally in both precious and base metals. Mr. Willoughby was most recently Vice President of Research and Analyst at Red Cloud Securities in Toronto. He spent two years as President and Director of Aldridge Minerals, a former Canadian based public exploration and development company with assets in Turkey and Papua New Guinea. Mr. Willoughby earned both a B.S. in Geology and a Masters in Business Administration from the University of Windsor.

For more information, visit the company’s website at www.BMRCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to BTRMF are available in the company’s newsroom at https://ibn.fm/BTRMF

Clinical research executives, data management specialists, and industry experts, are all invited to attend the 3rd Risk Based Quality Management Summit that will be held from April 25-26, 2023 at the Le Méridien, in Philadelphia. The summit will be focused on conferring the details of executing data flow process maps, data monitoring tools, audit trails, and quality tolerance limits.

RBQM is now being embraced to address the significant increase in research duration, cost, and complexity of clinical research. The newest version of the Good Clinical Practice (“GCP”) quality standard extends the RBM approach to every facet of study execution, implementing the principles to all parts of quality management needing effective centralized monitoring systems and processes.

The 3rd Annual RBQM Summit will provide real-world lessons from businesses on the leading edge of execution and promote RBQM. This two-day event will feature plenary keynotes from biopharma thought leaders, focused on explicit functions and issues within clin ops, as well as research enterprise and innovation, with interactive and informal breakout discussion groups and networking.

Featured Topics and Discussions:

• Nurture a culture of efficiency and ensure end-to-end quality, cost management, and reliability
• Improve monitoring to include remote data monitoring, site and central monitoring
• Refine skills for risk identification, response, and mitigation
• Ensure the efficiency of QTLs and KRIs
• Ways to respond to central monitoring outputs

A risk-based approach to clinical trials helps to decrease trial costs and complexity while maximizing the R&D budget. The best practices in RBQM influence decentralized trials and clinical study methodology, focusing on risk-based data review including central and site monitoring.

The 3rd Risk Based Quality Management Summit is designed to help you establish cross-functional risk-management teams to manage your clinical trials, decreasing risks and improving drug development. Attendees will get access to valuable information on relevant matters in the risk-based management and monitoring space. Attendees can make the most of this engagement opportunity featuring live sessions, downloadable resources, and Q&A sessions.

Register today and hear the experts share advanced approaches and best practices to optimize data quality and improve risk management and trial efficiency.

To learn more, please visit https://ibn.fm/FYN

• Owing to a litany of drivers, the days of “green” or “alternative” energy will be terms of the past, replaced by simply “energy” as they are the standard
• GeoSolar Technologies is pioneering the home energy transition with its solar-based, all-electric, high-efficiency home model
• Transitioning homes in the U.S. to GeoSolar’s SmartGreen(TM) homes would be equivalent to removing about 65% of the country’s gas-powered vehicles as far as carbon emissions

“As one era ends, another is just getting started – and we can’t wait to show you what we’ve got coming.” That was a tweet a few weeks ago from Ford New Europe, a message regarding the Company’s transition towards electric vehicles. It’s an appropriate sentiment towards a broader paradigm shift at global scale to say a warm goodbye to legacy technologies, they’ve served us well, while embracing the next generation of innovation that will serve us even better. In the way that Ford is a leader is shepherding in the EV revolution, GeoSolar Technologies (“GST”) is re-imagining homes by using modern technology.

Right now, there are buzzwords that continue to circulate like “EV” and “green energy,” but it is not hard to imagine that the adjectives will be dropped in the coming decades. When every car is powered by electric, won’t they just become “vehicles?” Seems that the adjective will flip to the minority of “gas-powered cars.”

The same is true for “green” or “alternative” energy.” One day it will simply be “energy,” perhaps only with the definer being the source (i.e., solar, wind, hydrogen, etc.). All the evidence points to that day coming. A few examples include:

• President’s Biden’s Inflation Reduction Act earmarked $369 billion in support of implementing alternative energies to reduce emissions
• The government issued a 10-year extension to the solar Investment tax credit
• The International Renewable Energy Agency forecast electricity consumption from renewables will rise from 25% in 2018 to 90% by 2050

Maybe because it is controversial and makes for good media theater, mainstream media tends to focus almost exclusively on EVs and shortcomings with utility-scale solar and wind projects that can be confusing to investors. Fact is, not everything that will be the future is still in the future.

GeoSolar Technologies is a pioneer in the home space with its SmartGreen(TM) Home system, the all-electric home of the future and model of building sustainability. The Company already has several demonstration homes built in its home state of Colorado, a region well known to experience a wide swing of weather conditions, including heavy snow and bitter cold in the winter and hot and sunny summers.

The SmartGreen(TM) model homes delivered some of the best scores ever on the HERS (Home Efficiency Ratings System) Index.

GeoSolar handles every bit of the comprehensive solution from initial analysis to funding and tax credits until installation of the final LED light bulb – which is powered by the new roof-mount photovoltaic solar panel system. Other components include a new geothermal unit for heating and cooling, electric heat pump, “envelope” insulation upgrade, EV charger, advanced whole home purification system, and digital air and energy monitoring application.

The system can be installed during new construction or retrofit into existing structures, typically within only a couple weeks.

Owing to the continuing decrease in prices of products and attractive government incentives, solar has emerged as the most attractive renewable power source for homes as it has the lowest levelized cost of energy (LCOE). LCOE is a measure of average net present cost of electricity generation over a lifetime, allowing for the comparison of different technologies of unequal life spans.

The impact on making this transition as it relates to mitigating climate change is all too often overlooked.

There were an estimated 141.95 million homes in the U.S. in 2021. If all of these homes were converted to SmartGreen(TM) homes, which can help eliminate more than the estimated 12,000-14,000 pounds of carbon per year an average household produces, we could reduce pollution by an estimated 1.9 trillion pounds per year.

To put that into perspective, Statista estimates there were 284.4 million cars in the U.S. in 2022. The U.S. Environmental Protection Agency estimates a typical passenger vehicle emits about 4.6 metric tons of carbon dioxide annually. At 2204.6 pounds per metric ton, that’s 10,141 pounds per vehicle, or 2.95 trillion pounds of carbon emissions. Transitioning homes to SmartGreen(TM) technologies would be like removing 65 percent of the gas-powered cars off the road today.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• SideChannel is committed to creating robust and top-tier cybersecurity programs for small and mid-market businesses (“SMBs”), thus helping them protect vital information and customers
• One of the companies SideChannel has helped achieve this goal is Virgin Voyages, which has expanded its engagement with SideChannel to improve its data privacy efforts with the addition of a virtual chief privacy officer (“vCPO”) from SideChannel
• The move builds on an earlier engagement, bolstering Virgin Voyages’ goal to protect the important information relating to its crew, sailors, and partners

A recent study by IBM Corp. (NYSE: IBM) revealed that the average cost of a data breach in the hospitality industry was $2.94 million in 2022, down from $3.03 million in 2021. This cost, the study highlights, encompasses detection and escalation costs (covering forensic and investigative activities, assessment and audit services, crisis management, and communications to executives and the board), lost business costs (including business disruption and revenue losses from system downtime, cost of lost customers and acquiring new clients, and reputation losses), notification costs, and post-breach response costs (https://ibn.fm/gsq06).

And although the average cost of data breaches within the hospitality industry is lower than in other industries, such as healthcare, financial, pharmaceuticals, technology, energy, retail, and so on, and is, thus, lower than the global average of $4.35 million, based on the findings of the study, the attack vectors that result in the unauthorized access to data remain an ever-present threat.

Unfortunately, according to SideChannel (OTCQB: SDCH) CEO Brian Haugli, “Some companies do not think of cybersecurity and privacy until an event forces them to.” But at that time, it is usually already too late. Preemptive protection is, therefore, recommended, and one company, Virgin Voyages, is doing just that.

A travel brand that delivers epic vacations at sea, Virgin Voyages is focused on proactively protecting its sailors and crew, boosting the cruise and vacation experience, as well as making the workplace safer. The brand, whose Lady ships sail on intercontinental cruises in the Americas and continentally in Europe’s Mediterranean waters, has truly international operations. The international nature of its business, however, creates an environment that is difficult to secure and protect.

In understanding these challenges and the need to protect the data and information of its crew, sailors, and partners, Virgin Voyages recently expanded an earlier engagement with SideChannel to enhance data privacy and protection from ship to shore. As part of the expanded agreement, Virgin Voyages has subscribed to SideChannel’s virtual chief privacy officer (“vCPO”) services, complementing the virtual chief information security officer (“vCISO”) services to which it had earlier subscribed. The vCPO will supplement and augment Virgin Voyages’ current efforts and team (https://ibn.fm/iPvO1).

“I feel very proud that our team’s work earned the trust of the Virgin Voyages crew and persuaded them to work even more closely with us,” said Haugli of the expanded engagement. “Virgin Voyages is propelled to preemptively protect their customers, staff, and all their data. We think that’s something worth celebrating.”

By providing vCPO and vCISO services, SideChannel aims to empower Virgin Voyages to achieve its stated environmental, social, and governance (“ESG”) goal of creating an “Epic Sea Change for All ” by, among others, providing a caring, safe, and secure workplace for its crewmembers (https://ibn.fm/F57LA).

Focused on making cybersecurity simple and accessible for small and mid-market businesses (“SMBs”), SideChannel helps its clients build robust cybersecurity and privacy programs led by expert and experienced vCISOs and vCPOs, who have previously worked as enterprise-level CISOs and CPOs. This way, the company enables client organizations to take control of their security, reduce risk, and ensure cybersecurity and privacy compliance.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• Lexaria’s DIAB-A22-1 animal model study just concluded, highlighting three positive outcomes, including an improvement in general activity, significant reductions in body weight, and improved triglyceride and cholesterol levels
• The study was undertaken by a third-party testing laboratory in Canada involving 24 obese and eight lean rats for a total of 32 male Zucker rats
• The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore its patented DehydraTECH(TM) technology application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more
• With its unique product offering, a growing list of patents, and unique market positioning, Lexaria is becoming a key player in the drug delivery technology space

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the completion of its DIAB-A22-1 animal model study, which explored the potential of the patented DehydraTECH(TM)-processed CBD to treat diabetes. Of note were three positive outcomes, including an improvement in general activity, reductions in body weight, and better triglyceride and cholesterol levels.

The study, undertaken by a leading, third-party testing laboratory in Canada, administered select Lexaria “DehydraTECH-CBD 2.0” formulations with doses of either 30 mg/Kg or 100 mg/Kg of body weight. It involved 24 obese and eight lean rats for a total of 32 male Zucker (“ZDF”) rats. As Lexaria’s first study in the diabetes animal model, the company is encouraged by the positive findings. Moreover, it is confident that the results indicate many prospective benefits worthy of further investigation together, possibly with other drugs that help to control glucose levels directly.

Lexaria set out to explore the therapeutic utility of DehydraTECH-CBD against diabetes in November 2022, on the heels of the success of its clinical studies on hypertension. The company’s management was optimistic that the results from the hypertension study would be replicated in the diabetes study, given that hypertension is twice as frequent in people with diabetes, and hypertensive patients are at greater risk of developing diabetes.

The success of this DIAB-A22-1 study marks a significant milestone for Lexaria, even as it continues to explore DehydraTECH’s application in various other areas, including nicotine replacement, epilepsy, hypertension, dementia and more. With DehydraTECH having proven to increase the effectiveness and the way active pharmaceutical ingredients enter the bloodstream, Lexaria is exploring its full potential for improving consumer products. Its efforts have seen the company awarded 28 patents, with more patents pending worldwide.

Diabetes is the 7th largest cause of death in the United States and accounts for an estimated value of $26.7 billion in the global diabetes devices market. Lexaria’s management is hopeful that its current efforts and studies will inch the company closer to taking advantage of this industry’s market potential. In 2021, the global diabetes drug market was estimated at $63.1 billion and is projected to hit $80.65 billion by 2027. With the company’s unique technology, a growing list of patents, and unique market positioning, Lexaria is set to capitalize on this growth and become a leader in the drug delivery technology space.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• A recent medical study found that psychedelic drugs showed promise as a treatment alternative for hard-to-treat depression
• Psychedelics were found to activate a greater number of serotonin 2A receptors then traditional antidepressant drugs, largely because of their ability to penetrated through cells’ fatty outer membranes
• The study reinforces the potential use of psychedelic drugs, and psilocybin in particular, as a treatment methodology for a variety of mental health related conditions
• Silo Pharma, a developmental stage biopharmaceutical company has long focused around merging traditional therapeutics with psychedelic research

In a study carried out between 2013 to 2016, researchers found that 8.1% of American adults aged 20 and over suffered from depression during any given 2-week period, with women nearly twice as likely than men to have had acute depression (https://ibn.fm/ygq4x). Whilst depression has long been treated with a combination of self-help, talking therapies and medicines, studies have previously found anti-depressant drug therapy to not be as effective as traditionally assumed. As a result, a recent study which found that psychedelic drugs could show promise as a therapeutic alternative in treating drug-resistant depression was greeted with some optimism within the sector (https://ibn.fm/cXz8A).

Over the course of the Covid-19 pandemic, rates of depression and anxiety skyrocketed, with many Americans turning to antidepressant medication to help them cope. Whilst 1 in 8 American adults were taking antidepressant drugs prior to the emergence of Covid (https://ibn.fm/FCKnZ), the figure rose by 18.6 percent in 2020 alone. However, a number of research papers have challenged the efficacy of these drugs as well as their assumed actions in the brain. Dr. David Hellerstein, professor of clinical psychiatry at the Columbia University Irving Medical Center addressed the query of whether anti-depressants worked during a recent interview with the New York Times:

“I think they do,” he said. “The best clinical trials and meta-analyses, most of them indicate that there’s some medication effect. [However] I would say it’s less than we would like it to be.”

Alternative treatments for depression have emerged that attempted to help the brain create new connections more efficiently – most notably ketamine and psychedelic therapy; initial findings have found these alternative treatments to be about as effective as antidepressants, improving depression in roughly 60 percent of the people who try them. It is precisely this issue which Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, has set out to tackle.

Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease and other rare neurological disorders. The company has recently entered into a number of studies designed to develop innovative solutions for previously underserved conditions. In doing so, the company recently entered into an agreement with Columbia University, granting it an option to license a number of assets under development including a prophylactic treatment for stress-induced disorders and PTSD.

Psychedelics such as psilocybin, the active compound found in magic mushrooms, have been known to plug into a structure called the serotonin 2 receptor, which bids the chemical messenger serotonin. Traditionally, antidepressants are designed to increase the levels of serotonin, so that when more of the serotonin neurotransmitters is sent to other parts of the brain, the person feels relief from depression. What the study found was that psychedelics were increasingly able to access receptors inside cells which standard antidepressants could not normally affect, thereby increasing the level of serotonin secreted within the brain – largely because of their ability to pass through cells’ fatty outer membranes to reach the additional receptors within.

The study now provides medical substance to a theory which has long been held by indigenous populations around the world – that the use of psychedelics, and psilocybin in particular could have beneficial effects for a variety of mental health related conditions. Although psilocybin was classified as a “breakthrough therapy” in treatment for severe depression by the U.S. Food and Drug Administration as far back as 2018 (https://ibn.fm/tXJM5), findings within the recent research report may now serve to support the development of psychedelics as a more mainstream medical treatment alternative for drug-resistant depression.

With psilocybin and psychedelic-based therapeutic treatment increasingly gaining favour amongst the medical community and with a rising prevalence of depression and mental disorders within modern society, forecasts have now projected the psychedelic drugs market to swell to a value of $6.8 billion annual by 2027, representing a CAGR of 16.3% within the forecast period of 2020 to 2027 (https://ibn.fm/mQJTH). As a frontrunner in the sector and with a number of research and drug developmental initiatives under way, Silo Pharma find themselves well positioned to capitalize on the growth of the sector going forward.

For more information, visit the company’s website at www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

• BiondVax is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, primarily for the treatment of infectious and autoimmune diseases
• The company is led by CEO Amir Reichman, with over 20 years of international experience as a biopharma expert
• Amir took company reins in 2021 and pivoted the mission and vision including diversifying risks
• With new focus and opportunity, BiondVax now developing an innovative alpaca-derived nanosized antibody (“NanoAb”) pipeline
• BiondVax is aggressively advancing new NanoAb therapeutic and prophylactic technologies owing to exclusive collaborations, previous pharma development experience and a state-of-the-art GMP manufacturing facility

Leveraging top-tier pharmaceutical industry leadership, extensive drug development expertise, a GMP biologics manufacturing facility, and strategic collaborations with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen (“UMG”), BiondVax Pharmaceuticals (NASDAQ: BVXV) is aggressively advancing development of a pipeline of diversified, commercially viable “NanoAb” products and platforms. The Jerusalem, Israel-headquartered biopharmaceutical company is initially focused on an innovative inhaled nanosized antibody treatment for COVID.

“Overall, the NanoAb platform is an incredible opportunity for BiondVax,” said BiondVax CEO Amir Reichman following the late 2021 signing of definitive agreements with MPI and UMG to develop and commercialize the innovative anti-COVID-19 NanoAb therapy (https://ibn.fm/ZlrYX). “It will serve as a basis for an exciting new pipeline of commercially attractive products to address unmet therapeutic needs of diseases such as psoriasis, psoriatic arthritis, asthma, and macular degeneration.”

The definitive agreements came only a few months after Amir’s appointment as CEO. Amir had previously served as Head of Global Vaccines Engineering, Core Technologies, and Asset Management at GSK Vaccines, headquartered in Belgium. Prior to taking up this role, he had served as Senior Director of Global Supply Chain Performance and Capabilities at the same company. Collectively, Amir has more than 20 years of international hands-on experience as a bio-pharma expert (https://ibn.fm/3XzzO). Leveraging this expertise, he made a few strategic changes to BiondVax when he took over as CEO on March 2, 2021.

“The first thing I have done as the new CEO, together with our Board of Directors, was to define a new mission and vision for BiondVax. Our new mission reflects an aspiration to focus on infectious diseases, which leverages BiondVax’s core competencies, while ensuring diversification of our corporate risks through the establishment of a new, broad product and platform pipeline,” Amir wrote in his first letter to shareholders (https://ibn.fm/JdTFq).

Although Amir and the board sought to diversify and mitigate risk by implementing strategic changes, the company still benefitted from its previous focus on developing the M-001 universal influenza vaccine candidate. Up until that point seven Phase 1/2 and 2 clinical trials conducted in Europe, Israel, and the USA, were completed, each with promising results. The success of these trials had guided the company’s execution of a pivotal phase 3 clinical trial in seven countries. Conducted between 2018 and 2020, the trial involved 12,400 participants and was completed on time and within budget (https://ibn.fm/tIbbo).

In many compelling ways, BiondVax punches well above its weight compared to biopharma companies of similar market cap: BiondVax gained extensive drug development expertise in these trials which is expected to be invaluable in the development and commercialization of the NanoAb pipeline. The company plans to undertake the first-in-human phase 1/2a clinical trial evaluating its inhaled anti-COVID-19 NanoAb therapy later this year. This rapid development path hinges not only on the expertise of its workforce and experience gained from the development of M-001 but also on its capabilities in biological drug development and manufacturing.

In 2018, BiondVax completed a 20,000-square-foot campus in Jerusalem that includes offices, laboratories, and a GMP biologics manufacturing facility, according to Amir (https://ibn.fm/7fdYz). The facility provides BiondVax with state-of-the-art GMP-ready manufacturing capabilities, enabling the company to handle pharmaceutical product development and manufacturing. As a result and following the closing of the agreements with its strategic collaborators, MPI and UMG, BiondVax’s strong team is putting the facility to use, mass producing the NanoAbs through recombinant protein manufacturing. These early batches have been used in a highly successful preclinical test of its inhaled COVID-19 NanoAb (https://ibn.fm/u5I73 and https://ibn.fm/ImvSC), and future batches are planned for the first-in-human phase 1/2a clinical trial planned for later this year.

BiondVax believes that its extensive drug development experience, experienced leadership, manufacturing capabilities, and product and platform pipeline ideally position it for in-licensing, acquisitions, and joint ventures, as well as rapid clinical development and manufacturing of new therapeutic and prophylactic technologies, beginning with the inhaled anti-COVID-19 NanoAb candidate.

By leveraging expertise, experience and collaborations, BiondVax aims to disrupt high value large market opportunities with its pipeline of innovative NanoAb therapeutics.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• McEwen Mining subsidiary McEwen Copper has been gaining increased financial support as it develops a major copper mine opportunity in Argentina described as one of the 10 largest undeveloped deposits in the world
• Mining giant Rio Tinto’s venture Nuton LLC has boosted last year’s $25 million investment into McEwen Copper with a new $30 million addition, all on top of the recent Stellantis investment of approximately $155 million
• The project in Argentina’s San Juan province benefits from a mining-friendly government and population
• The demand for copper is expected to continue to grow as a result of its importance to green energy transition efforts and ongoing challenges the metal’s supply stream faces

The strength of metals explorer McEwen Copper’s profile and of its parent company McEwen Mining (NYSE: MUX) (TSX: MUX) was further demonstrated recently by a second investment of $30 million, at $18.75 per share  boost to an investment made by mining and metals giant Rio Tinto’s venture Nuton LLC. Nuton first invested $25 million last August, at $10 per share. as part of a private placement to help fund McEwen Copper’s development of its Los Azules Project in Argentina’s mining friendly province of San Juan (https://ibn.fm/cAKBx).

The Nuton investment is in addition to the recently announced closure of an  investment by automotive multinational Stellantis, the world’s 4th largest automobile manufacturer, of approximately $155 million.

McEwen Copper Inc. holds 100 percent interest in the Los Azules copper project and McEwen Mining owns about 52 percent of McEwen Copper, Nuton and Stellantis each own 14.2% and Rob McEwen owns 13.8%.

“We are extremely pleased to have Nuton’s strong continued participation in McEwen Copper. Together we are exploring new technologies that save energy, water, time and capital in the pursuit of delivering green copper to Argentina and the world, a product that will contribute to the electrification of transportation and the protection of our atmosphere,” McEwen Copper CEO Rob McEwen stated (https://ibn.fm/WfNmr).

Last year MINING.COM, and its sister company Miningintelligence, included the Los Azules Project as being among the 10 largest undeveloped copper deposits in the world, noting its current copper resources at an estimated 10.2 billion pounds at a grade of 0.48 percent Cu (Indicated category) and an additional 19.3 billion pounds at a grade of 0.33 percent Cu (Inferred category) (https://ibn.fm/TlMjj).

Copper is regarded as a bellwether metal signaling the direction of the global economy, and while prices have remained below 2021’s peak their northward trend has generated excitement among market watchers this year (https://ibn.fm/ssDgC). The metal is vital for the transition to green energy that world governments and climate change activists have been seeking, and demand for it is expected to continue climbing even as the supply chain faces challenges that new productivity in Argentina could help to alleviate (https://ibn.fm/1qfKN).

Los Azules has been popular with the local government because of the pioneering efforts to make mine development more environmentally friendly and because of the employment opportunities it provides hundreds of workers in the region (https://ibn.fm/9vXUc).

McEwen Copper states it is well-funded into 2024. Updated Preliminary Economic Assessment (“PEA”) expected in early Q2 2023 and an IPO in late H2 or early 2024.

For more information, visit the company’s website at www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX